GLOBAL ANALGESICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Market Segmentation

• By Drug Class (Revenue, USD Bn, 2021 - 2033)

  • Analgesic Combinations (Includes Narcotic Analgesic Combinations)
    • Acetaminophen + Aspirin
    • Acetaminophen + Aspirin + Caffeine
    • Acetaminophen + Butalbital
    • Acetaminophen + Butalbital + Caffeine
    • Acetaminophen + Caffeine
    • Acetaminophen +Caffeine + Isometheptene Mucate
    • Acetaminophen + Caffeine + Magnesium Salicylate
    • Acetaminophen + Diphenhydramine
    • Aspirin + Butalbital + Caffeine
    • Codeine + Acetaminophen
    • Codeine + Acetaminophen + Butalbital + Caffeine
    • Codeine + Aspirin + Butalbital + Caffeine
    • Dihydrocodeine + Acetaminophen + Caffeine
    • Hydrocodone + Acetaminophen
    • Hydrocodone + Ibuprofen
    • Ibuprofen + Diphenhydramine
    • Naproxen + Diphenhydramine
    • Oxycodone + Acetaminophen
    • Tramadol + Acetaminophen
  • Antimigraine Agents
    • Almotriptan
    • Dihydroergotamine Nasal
    • Eletriptan
    • Ergotamine
    • Ergotamine + Caffeine
    • Frovatriptan
    • Naratriptan
    • Rizatriptan
    • Sumatriptan Injection
    • Sumatriptan + Naproxen
    • Zolmitriptan
  • Cox-2 Inhibitors (Celecoxib)
  • Acetaminophen and Miscellaneous Analgesics
    • Acetaminophen
    • Ziconotide
  • Narcotic Analgesics
    • Alfentanil
    • Buprenorphine
    • Butorphanol (Injection)
    • Codeine
    • Fentanyl
    • Hydrocodone
    • Hydromorphone
    • Levorphanol
    • Meperidine
    • Methadone
    • Morphine
    • Nalbuphine
    • Oxycodone
    • Oxymorphone
    • Tramadol
    • Tapentadol
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • More COX-1 selective
      • Flurbiprofen
      • Ketorolac (nasal)
      • Ketoprofen
      • Tolmetin
      • Relatively nonselective
      • Ibuprofen
      • Naproxen
    • Less than 50-fold COX-2 selective
      • Indomethacin
      • Sulindac
      • Piroxicam
      • Mefenamic acid
      • Meloxicam
      • Diclofenac
      • Celecoxib
      • Etodolac
    • Salicylates
      • Aspirin
      • Diflunisal
      • Magnesium salicylate
      • Salsalate
    • CGRP inhibitors
      • Erenumab
      • Galcanezumab
      • Fremanezumab
      • Rimegepant
      • Ubrogepant
      • Atogepant
      • Eptinezumab
      • Zavegepant

• By Indication (Revenue, USD Bn, 2021 - 2033)

  • Migraine
    • Chronic Migraine
    • Migraine Prevention
  • Headache  and Cluster Headaches
  • Allergic Rhinitis
  • Anxiety
  • Back Pain
  • Cold Symptoms
  • Fever
  • Hangover
  • Influenza
  • Insomnia
  • Muscle Pain
  • Osteoarthritis
  • Pain
  • Pain/Fever
  • Period Pain
  • Postoperative Pain
  • Premenstrual Dysphoric Disorder
  • Premenstrual Syndrome
  • Rheumatoid Arthritis
  • Sinusitis
  • Ankylosing Spondylitis
  • Chronic Pain
  • Familial Adenomatous Polyposis
  • High Blood Pressure
  • Juvenile Rheumatoid Arthritis
  • Spondylarthritis
  • Chiari Malformation
  • Eustachian Tube Dysfunction
  • Neck Pain
  • Plantar Fasciitis
  • Sciatica
  • Transverse Myelitis
  • Cough
  • Opioid Use Disorder
  • Aseptic Necrosis
  • Bartter Syndrome
  • Bursitis
  • Chronic Myofascial Pain
  • Costochondritis
  • Diffuse Idiopathic Skeletal Hyperostosis
  • Dysautonomia
  • Frozen Shoulder
  • Gout, Acute
  • Inflammatory Conditions
  • NSAID-Induced Ulcer Prophylaxis
  • Patent Ductus Arteriosus
  • Polyarticular Juvenile Idiopathic Arthritis
  • Polymyalgia Rheumatica
  • Radiculopathy
  • Spondylolisthesis
  • Temporomandibular Joint Disorder
  • Tendonitis
  • Toothache
  • Anesthetic Adjunct
  • Breakthrough Pain
  • Diabetic Peripheral Neuropathy
  • Diarrhea
  • Labor Pain
  • Light Sedation
  • Neonatal Abstinence Syndrome
  • Opiate Dependence - Induction
  • Opiate Dependence - Maintenance
  • Opiate Withdrawal
  • Sedation
  • Angina
  • Angina Pectoris Prophylaxis
  • Antiphospholipid Syndrome
  • Gas
  • Heart Attack
  • Indigestion
  • Ischemic Stroke
  • Ischemic Stroke, Prophylaxis
  • Kawasaki Disease
  • Lupus
  • Myocardial Infarction, Prophylaxis
  • Niacin Flush
  • Prevention of Thromboembolism in Atrial Fibrillation
  • Prosthetic Heart Valves - Thrombosis Prophylaxis
  • Prosthetic Heart Valves, Mechanical Valves - Thrombosis Prophylaxis
  • Revascularization Procedures, Prophylaxis
  • Rheumatic Fever
  • Thromboembolic Stroke Prophylaxis
  • Transient Ischemic Attack
  • Others

• By Dosage Form (Revenue, USD Bn, 2021 - 2033)

  • Tablet
  • Capsule
  • Injectable
  • Patches
  • Roll On
  • Spray
  • Creams, Gels and Ointments
  • Others (Suppository, Nasal etc.)

• By Drug Composition (Revenue, USD Bn, 2021 - 2033)

  • Single
  • Combination

• By Availability (Revenue, USD Bn, 2021 - 2033)

  • OTC
  • Rx

• By Type (Revenue, USD Bn, 2021 - 2033)

  • Branded
  • Generics

• By Gender (Revenue, USD Bn, 2021 - 2033)

  • Male
  • Female

• By Age Group (Revenue, USD Bn, 2021 - 2033)

  • Pedatric/Infant
  • Children
  • Adult
  • Geriatrics

• By Route of Administration (Revenue, USD Bn, 2021 - 2033)

  • Oral/Enteral
  • Parenteral
  • Topical (Including Patches)
  • Others (Rectal, etc.)

• By Distribution Channel (Revenue, USD Bn, 2021 - 2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• By Region (Revenue, USD Bn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa